|
| |
Nutrition 21Leveraging its biotechnology heritage, Nutrition 21 is pioneering an effort to use patented technology, pharmaceutical research and strategic marketing and distribution partnerships to build its position in therapeutic markets. The Company is targeting specific disease states and age related health care concerns through its Chromax®, Diachrome®, Iceland Health®, and Selenomax® brands. The disease states include obesity/pre-diabetes, metabolic syndrome, diabetes, cardiovascular health, arthritis, mood disorders, and immune system dysfunction (HIV).
Nutrition 21 relies on large scale double blind-placebo controlled clinical trials as a key element of its product development and marketing strategy. The Company’s objective is to translate its scientific findings into trusted brands recognized for their measurable contribution to improving health and reducing cost of care. The Company earns the trust of consumers with endorsements from healthcare professionals and by getting our products adopted as a standard therapy recommended by doctors and health care professionals.
Different from most biotechnology or pharmaceutical companies, the Company is focused on developing products that are marketed under the Dietary Supplement Health and Education Act (DSHEA) regulatory pathway. The Food and Drug Administration’s (FDA) regulations for the supplement category enable companies to bring products to market in less time and with less cost than is required for FDA drug approval. Different from most nutritional supplement companies, clinical substantiation is a requirement for our product development program.
Recent Publications by Nutrition 21: |  |
Omega-3 fatty acids and the cardiometabolic syndrome.
Benefits of fish consumption in patients with the cardiometabolic syndrome... | 25th March, 2009
| Nutrition 21,
| J Cardiometab Syndr. 2008 Fall;3(4):244-53.
DOI Direct Link |
Chromium picolinate does not produce chromosome damage.
Chromium picolinate (CrPic) is used as a dietary supplement and has... | 11th July, 2008
| Research and Development, Nutrition 21 Inc, 4 Manhattanville Road,
| Toxicol In Vitro. 2008 Apr;22(3):819-26. Epub 2007 Dec 25.
DOI Direct Link |
Parathyroid hormone may be a cancer promoter - an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D.
Epidemiological studies reporting an inverse association between sunlight... | 10th June, 2000
| Nutrition 21/AMBI, San Diego, CA, USA.
| Med Hypotheses. 2000 Mar;54(3):475-82.
DOI Direct Link |
Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity.
Amino acids modulate the secretion of both insulin and glucagon; the... | 25th March, 2000
| Nutrition 21/AMBI, San Diego, CA, USA.
| Med Hypotheses. 1999 Dec;53(6):459-85.
DOI Direct Link |
Press Releases on Nutrition 21:
|
 |
| Nutrition 21 Announces Addition of Innovative New Probiotic + Omega-3 Fish Oil Combination Product |
6th November, 2009 |
Nutrition 21, Inc. |
PURCHASE, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (OTC Bulletin Board: NXXI), the developer and marketer of ingredients and finished products under the Iceland Health, Chromax, and
|
| Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results |
4th November, 2009 |
Nutrition 21, Inc. |
PURCHASE, N.Y., Nov. 4 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (OTC Bulletin Board: NXXI), the developer and marketer of ingredients and finished products under the Iceland Health®, Chromax®,
|
| Nutrition 21, Inc. Announces Successful Transition to OTC Bulletin Board |
23rd October, 2009 |
Nutrition 21, Inc. |
PURCHASE, N.Y. , Oct. 23 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (OTC Bulletin Board: NXXI), the developer and marketer of nutritional supplements under the Iceland Health®, Chromax® and
|
| Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line |
7th July, 2009 |
Nutrition 21, Inc. |
CONTACT:
Lytham Partners, LLC
Joe Diaz, Joe Dorame, Robert Blum
(602) 889-9700
SOURCE Nutrition 21, Inc.
|
| EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements |
30th June, 2009 |
Nutrition 21, Inc. |
The European Food Safety Authority (EFSA) concludes no safety concerns for the use of chromium picolinate in food supplements, in response to Nutrition 21's Application to market Chromax(R)
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 229 times since April 2007, the link to the organisation's website has been followed 36 times This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Nutrition 21 |
